HC Wainwright Estimates TG Therapeutics FY2029 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of TG Therapeutics in a research note issued to investors on Monday, October 6th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will post earnings of $3.15 per share for the year. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

Several other brokerages also recently weighed in on TGTX. The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a research note on Thursday, July 10th. B. Riley lifted their price objective on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research report on Saturday, September 27th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $49.00.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $36.76 on Tuesday. The company has a 50-day moving average price of $31.54 and a two-hundred day moving average price of $35.35. The stock has a market cap of $5.83 billion, a price-to-earnings ratio of 99.35 and a beta of 1.97. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. TG Therapeutics has a 52 week low of $21.16 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same quarter in the previous year, the business posted $0.04 earnings per share. The business’s quarterly revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS.

Insider Activity

In other news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director owned 94,061 shares in the company, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.64% of the stock is owned by company insiders.

Institutional Trading of TG Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TGTX. Ameritas Advisory Services LLC purchased a new position in TG Therapeutics in the second quarter valued at about $25,000. Johnson Financial Group Inc. bought a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $25,000. NBC Securities Inc. increased its holdings in TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 823 shares during the last quarter. Golden State Wealth Management LLC raised its position in TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 433 shares in the last quarter. Finally, SVB Wealth LLC acquired a new stake in TG Therapeutics in the first quarter valued at approximately $37,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.